Needham Remains a Hold on Merit Medical Systems (MMSI)

Needham analyst Michael Matson maintained a Hold rating on Merit Medical Systems (MMSIResearch Report) today. The company’s shares closed last Tuesday at $43.15.

According to, Matson is a 5-star analyst with an average return of 6.3% and a 57.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merit Medical Systems with a $43.50 average price target.

See today’s analyst top recommended stocks >>

Based on Merit Medical Systems’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $244 million and GAAP net loss of $3.15 million. In comparison, last year the company earned revenue of $238 million and had a net profit of $6.2 million.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates advanced non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger and William Padilla in July 1987 and is headquartered in South Jordan, UT.